Eukaryotic initiation factor 4A2 promotes experimental metastasis and oxaliplatin resistance in colorectal cancer
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Deregulation of protein translation control is a hallmark of cancers. Eukaryotic initiation factor 4A2 (EIF4A2) is required for mRNA binding to ribosome and plays an important role in translation initiation. However, little is known about its functions in colorectal cancer (CRC). METHODS: Analysis of CRC transcriptome data from TCGA identified that EIF4A2 was associated with poor prognosis. Immunohistochemistry study of EIF4A2 was carried out in 297 paired colorectal tumor and adjacent normal tissue samples. In vitro and in vivo cell-biological assays were performed to study the biological functions of EIF4A2 on experimental metastasis and sensitivity to oxaliplatin treatment. Bioinformatic prediction, chromatin immunoprecipitation (ChIP) and dual-luciferase reporter assay were carried out to unveil the transcription factor of EIF4A2 regulation. RESULTS: EIF4A2 Expression is significantly higher in colorectal tumors. Multivariate analysis suggests EIF4A2 as an independent predictor of overall, disease-free and progression-free survival. Dysfunction of EIF4A2 by genetic knock-down or small-molecule inhibitor silvestrol dramatically inhibited CRC invasion and migration, sphere formation and enhanced sensitivity to oxaliplatin treatment in vitro and in vivo. Notably, EIF4A2 knock-down also suppressed lung metastasis in vivo. qRT-PCR and immunoblotting analyses identified c-Myc as a downstream target and effector of EIF4A2. ChIP and dual-luciferase reporter assays validated the bioinformatical prediction of ZNF143 as a specific transcription factor of EIF4A2. CONCLUSIONS: EIF4A2 promotes experimental metastasis and oxaliplatin resistance in CRC. Silvestrol inhibits tumor growth and has synergistic effects with oxaliplatin to induce apoptosis in cell-derived xenograft (CDX) and patient-derived xenograft (PDX) models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Self-citationTargeting the translation machinery in cancer
Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4505 · Cited by 799
The Scanning Mechanism of Eukaryotic Translation Initiation
Hinnebusch, A. G. (2014) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060713-035802 · Cited by 798
McDonald, E. R., de Weck, A., Schlabach, M. R., Billy, E., Mavrakis, K. J., Hoffman, G. R., Belur, D., Castelletti, D., Frias, E., Gampa, K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.005 · Cited by 658
RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer
Wolfe, A. L., Singh, K., Zhong, Y., Drewe, P., Rajasekhar, V. K., Sanghvi, V. R., Mavrakis, K. J., Jiang, M., Roderick, J. E., Van der Meulen, J., et al. (2014) · Nature · doi:10.1038/nature13485 · Cited by 635
Targeting the eIF4F Translation Initiation Complex: A Critical Nexus for Cancer Development
Pelletier, J., Graff, J., Ruggero, D., & Sonenberg, N. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2789 · Cited by 367
Translational Repression and eIF4A2 Activity Are Critical for MicroRNA-Mediated Gene Regulation
Meijer, H. A., Kong, Y. W., Lu, W. T., Wilczynska, A., Spriggs, R. V., Robinson, S. W., Godfrey, J. D., Willis, A. E., & Bushell, M. (2013) · Science · doi:10.1126/science.1231197 · Cited by 326
Ju, H.-Q., Gocho, T., Aguilar, M., Wu, M., Zhuang, Z.-N., Fu, J., Yanaga, K., Huang, P., & Chiao, P. J. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0420 · Cited by 137
Self-citationMolecular Pathways: The eIF4F Translation Initiation Complex—New Opportunities for Cancer Treatment
Malka-Mahieu, H., Newman, M., Désaubry, L., Robert, C., & Vagner, S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2362 · Cited by 105
Galan, J. A., Geraghty, K. M., Lavoie, G., Kanshin, E., Tcherkezian, J., Calabrese, V., Jeschke, G. R., Turk, B. E., Ballif, B. A., Blenis, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405601111 · Cited by 85
Cited by
Patient-derived xenograft models in cancer therapy: technologies and applications
Liu, Y., Wu, W., Cai, C., Zhang, H., Shen, H., & Han, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01419-2 · Cited by 494
Colorectal liver metastasis: molecular mechanism and interventional therapy
Zhou, H., Liu, Z., Wang, Y., Wen, X., Amador, E. H., Yuan, L., Ran, X., Xiong, L., Ran, Y., Chen, W., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00922-2 · Cited by 298
Self-citationAmidino-Rocaglates: A Potent Class of eIF4A Inhibitors
Chu, J., Zhang, W., Cencic, R., Devine, W. G., Beglov, D., Henkel, T., Brown, L. E., Vajda, S., Porco, J. A., & Pelletier, J. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.08.008 · Cited by 74
“However, this remains an area of interest to explore as there is evidence suggesting that eIF4A2 may have tumor promoting effects (Chen et al., 2019) and in certain cancers, eIF4A2 is the predominant paralog (Wolfe et al.”
Exploring and bypassing resistance to targeted therapies in colorectal cancer
Favier, S., Xiong, W., Chalabi-Dchar, M., Chettab, K., Piercey, O., Wu, T., Fenouil, T., Albaret, M.-A., Jordheim, L. P., Diaz, J.-J., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118741 · Cited by 12
Dong, J., He, J., Zhang, Z., Zhang, W., Li, Y., Li, D., Xie, H., Zuo, W., Tang, J., Zeng, Z., et al. (2022) · Journal of Proteomics · doi:10.1016/j.jprot.2022.104598 · Cited by 10
Self-citation
Metadata
- Authors
- Chen, Z.-H., Qi, J.-J., Wu, Q.-N., Lu, J.-H., Liu, Z.-X., Wang, Y., Hu, P.-S., Li, T., Lin, J.-F., Wu, X.-Y., Miao, L., Zeng, Z.-L., Xie, D., Ju, H.-Q., Xu, R.-H., & Wang, F.
- Venue
- Journal of Experimental & Clinical Cancer Research
- Published
- 2019-05-14
- Volume
- 38
- Issue
- 1
- Pages
- 196-196
- ISSN
- 0392-9078 (ISSN-L)
- 1756-9966
- OpenAlex
- W2947574880
- Cited by
- 63
- References
- 11
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Eukaryotic initiation factor 4A2 promotes experimental metastasis and oxaliplatin resistance in colorectal cancer. https://app.cochat.ai/papers/10.1186/s13046-019-1178-z
- The paper
- Chen, Z.-H., Qi, J.-J., Wu, Q.-N., Lu, J.-H., Liu, Z.-X., Wang, Y., Hu, P.-S., Li, T., Lin, J.-F., Wu, X.-Y., Miao, L., Zeng, Z.-L., Xie, D., Ju, H.-Q., Xu, R.-H., & Wang, F. (2019). Eukaryotic initiation factor 4A2 promotes experimental metastasis and oxaliplatin resistance in colorectal cancer. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-019-1178-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.